Xenetic Biosciences Q3 revenue up 67.2% on royalty gains

Xenetic Biosciences

13/11/2025 13:53

Overview

Xenetic Q3 revenue rises 67.2% yr/yr, driven by increased royalty revenue

Net loss for Q3 2025 was $0.5 mln, with increased R&D expenses

Company secured $3.9 mln from October 2025 offering to extend cash runway

Outlook

Xenetic advances DNase technology towards Phase 1 clinical trials for solid tumors

Company plans to invest in pre-clinical efforts and exploratory studies

Xenetic partners with PeriNess for clinical trials in Israeli medical centers

Result Drivers

CASH RUNWAY EXTENSION - $3.9 mln secured from October 2025 offering to support research and development

INCREASED R&D EXPENSES - R&D expenses rose due to manufacturing development and pre-clinical research

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$500,000


Press Release: ID:nACSBZtt5a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)